Stock NERV MINERVA NEUROSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq
Other stock markets
 21:30:00 30/04/2024 BST 		5-day change 1st Jan Change
2.36 USD -2.08% Intraday chart for Minerva Neurosciences, Inc. -6.72% -61.63%
02-27 Sector Update: Health Care Stocks Ease Late Afternoon MT
02-27 Top Midday Decliners MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Ease Late Afternoon
Top Midday Decliners
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Declining Late Wednesday
Sector Update: Health Care
Top Midday Gainers
Minerva Neurosciences to Raise $20 Million Through Private Placement of Common Shares
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms
Minerva Neurosciences, Inc. Announces Board Changes
Top Midday Gainers
FDA Files Minerva Neurosciences's NDA for Roluperidone to Treat Schizophrenia Symptoms; Shares Jump 61% Midday
Minerva Neurosciences, Inc. Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NERV Stock
  4. News Minerva Neurosciences, Inc.
  5. Other languages